Drugs / aIIV4
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04576702 Comparator | Oct 2020 → Mar 2021 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aIIV4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04576702 ↗ |
| Known as | aQIV | “Eligible participants aged ≥50 years were randomised 1: 1:1:1 to receive aQIVc (n = 116), a non-adjuvanted quadrivalent cell-based influenza vaccine (QIVc; n = 119), an...” PMID 39946829 ↗ Feb 2025 |
| Modality | Vaccine | “Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine” NCT04576702 ↗ |
| Route | Intramuscular | “aIIV4 will be administered as a single dose intramuscularly on Day 1” NCT04576702 ↗ |